Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib for Relapsed/Refractory DLBCL
NCT03376958Phase 4Completed
- Sponsor
- Zhengzhou University
- Start
- Jan 2017
- Primary completion
- Feb 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of Rivoceranib in diffuse large B-cell lymphoma (DLBCL), sponsored by Zhengzhou University. Started Jan 2017; status: completed.
02
Drugs
Rivoceranib
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT03376958.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03376958.